Summary
This blog provides information regarding the Avience Biomedicals IPO, including its fundamentals, valuation, key dates, and issue details.
The firm operates as a manufacturer of IVD and medical devices, catering to both B2B and B2C markets.
The issue size is ₹30 crore with a fresh issue of 14,53,800 shares. The current GMP indicates positive returns ahead of the listing.
Avience Biomedicals IPO consists of an entirely fresh issue of 14,53,800 shares. Their nominal value is ₹10 per share. The value of the total issue amounts to ₹30 crore. The subscription window opens on June 18, 2026. Bids will be accepted until the offer closes on June 22, 2026. The company has planned to allot the shares on June 23, 2026. The IPO will make its NSE SME debut on June 25, 2026.
It is a book-building offering set within the price range of ₹196 to ₹208. Each lot is made up of 600 shares. Individual investors can participate by applying for a minimum of two lots (1,200 shares), which will require an investment of ₹2,49,600. Bidding for the sNII category starts at three lots (1,800 shares) amounting to ₹3,74,400. The bNII participants must apply with ₹11,23,200 for 9 lots (5,400 shares).
Avience Biomedicals IPO Details
Here is an overview of the key particulars related to this offering:
| Particulars | Details |
| Bidding Opens | Jun 18, 2026 |
| Bidding Closes | Jun 22, 2026 |
| Face Value | ₹10 per share |
| Issue Type | Bookbuilding |
| Price Band | ₹196 to ₹208 |
| Issue Price | |
| Listing at | NSE SME |
| Lot Size | 600 Shares |
| Fresh Issue | 13,71,600 shares (₹29 Crore) |
| Market Maker Shares | 82,200 shares (₹2 Crore) |
| Offer for Sale (OFS) | |
| Total Issue | 14,53,800 shares (₹30 Crore) |
| Minimum Investment | ₹2,49,600 |
Avience Biomedicals IPO Timeline
The offering is planned to take place according to the following schedule:
| Particulars | Details |
| Bidding Opens | June 18, 2026 |
| Bidding Closes | June 22, 2026 |
| Proposed Allotment | June 23, 2026 |
| Refunds Start On | June 24, 2026 |
| Share Credit to Demat | June 24, 2026 |
| Listing Scheduled | June 25, 2026 |
| Cut-off for UPI mandate | 5:00 PM on June 22, 2026 |
Avience Biomedicals Key Performance Indicators
The given table outlines Avience Biomedicals’ KPIs:
| Period Ended | 31-01- 2026 | 31-03-2025 | 31-03-2024 |
| ROE (%) | 22.38 | 49.89 | 34.47 |
| ROCE (%) | 16.99 | 24.88 | 17.97 |
| Debt-Equity (times) | 0.94 | 0.97 | 2.44 |
| RoNW (%) | 22.38 | 49.89 | 34.47 |
| PAT Margin (%) | 15.86 | 8.83 | |
| EBITDA Margin (%) | 24.70 | 25.22 | 17.01 |
| Price Book Value | 2.94 | 3.68 | – |
Avience Biomedicals Financials
The financial metrics of Avience Biomedicals are outlined below:
| Period Ended | 31-01- 2026 | 31-03-2025 | 31-03-2024 |
| Total Assets (in ₹ lakh) | 6,607.20 | 5,652.46 | 3,465.08 |
| Revenue (in ₹ lakh) | 4,194.28 | 4,596.74 | 2,437.2 |
| Profit (in ₹ lakh) | 573.96 | 723.18 | 214.11 |
Avience Biomedicals IPO Subscription Status
| Date | QIB (Ex Anchor) | NII* | Individual Investors | Total |
|---|---|---|---|---|
| Jun 18 (Day 1) | 0.00 | 11.18 | 13.41 | 9.12 |
Avience Biomedicals IPO GMP
The latest grey market activity suggests strong interest in the Avience Biomedicals IPO. With a GMP of ₹75 as of June 17, 2026, the expected listing price stands at approximately ₹283, implying a potential upside of 36.06%. The premium has also strengthened from ₹63 in the previous session.
| GMP Date | GMP | Est. Listing Price | Est. Profit* | Last Updated |
|---|---|---|---|---|
| 18-06-2026 Open | ₹75 ─ | ₹283 (36.06%) | ₹45,000 | 18-Jun-2026 14:58 |
| 17-06-2026 | ₹75 ▲ | ₹283 (36.06%) | ₹45,000 | 17-Jun-2026 23:33 |
| 16-06-2026 | ₹63 ▼ | ₹271 (30.29%) | ₹37,800 | 16-Jun-2026 23:30 |
| 15-06-2026 | ₹70 ▲ | ₹278 (33.65%) | ₹42,000 | 15-Jun-2026 23:30 |
| 14-06-2026 | ₹0 ─ | ₹ (0.00%) | 14-Jun-2026 5:55 | |
| 13-06-2026 | ₹0 ─ | ₹ (%) | 13-Jun-2026 21:50 |
Note: The GMP figures are indicative in nature and should only be used as a sentiment indicator rather than a guarantee of listing gains.
Avience Biomedicals IPO Reservation
The IPO allocates shares across different investor segments in the following manner:
| Investor Category | Reservation |
| Market Maker Shares | 82,200 |
| QIB Shares | 6,83,400 |
| NII (HNI) Shares | 2,07,000 |
| Retail Shares | 4,81,200 |
| Total Shares | 14,53,800 |
Avience Biomedicals IPO Lot Size
Applicants must adhere to the given lot size structure while placing bids.
| Investor Type | Lots | Shares | Amount |
| Individual Investors (Minimum) | 2 | 1,200 | ₹2,49,600 |
| Individual Investors (Maximum) | 2 | 1,200 | ₹2,49,600 |
| S-HNI (Minimum) | 3 | 1,800 | ₹3,74,400 |
| S-HNI (Maximum) | 8 | 4,800 | ₹9,98,400 |
| B-HNI (Minimum) | 9 | 5,400 | ₹11,23,200 |
Avience Biomedicals IPO Anchor Investors
Details relating to the anchor investor portion of the offering are as follows:
| Particulars | Details |
| Anchor Bidding Opens | June 17, 2026 |
| Shares Offered | Up to 60% of the QIB Portion |
| Portion Size | 4,09,800 |
| Lock-in for 50% Shares (30 Days) | July 23, 2026 |
| Remaining Shares Lock-in (90 Days) | September 21, 2026 |
Avience Biomedicals IPO Prospectus
For a more detailed understanding of the issue, refer to the links provided below.
About Avience Biomedicals
Founded in 2019, Avience Biomedicals makes medical consumables focusing on in vitro diagnostics (IVD) and the medical devices segment. Dharam Deo Choudhary heads the organisation as the managing director. He is supported by other members of the promoter group, Janardan Pal, Deepa Choudhary and Ram Nagina Choudhary.
Avience Biomedicals manufacturing facility in Noida produces a range of diagnostic products, including rapid test kits, Viral Transport Media (VTM), serology products, biochemistry analysers, and reagents. It operates in both business-to-business (B2B) and business-to-consumer (B2C) markets, catering to hospitals, pathology laboratories, and research centres across India and overseas.
| IPO Registrar | Skyline Financial Services |
| Lead Manager | Fintellectual Corporate Advisors |
Avience Biomedicals IPO Objectives
The net proceeds will be utilised for following requirements:
| Particulars | Amount (in ₹ lakh) |
| Setting up a production facility in Yamuna Expressway Industrial Development Authority (YEIDA) Medical Park | 1,595.53 |
| Working capital needs | 825.00 |
| General corporate purposes | – |
Strengths of Avience Biomedicals
Avience Biomedicals has established a presence in its operating segment through a range of operational and strategic strengths highlighted below.
- Innovative Product Portfolio: The company offers a broad range of IVD rapid test kits, diagnostic consumables, biochemistry analysers, and medical devices. Its association with Mindray further strengthens its product offering and market reach.
- Skilled Workforce: Its operations are supported by professionals across manufacturing, quality control, regulatory affairs, technical support, and product development, enabling efficient execution and continuous improvement.
- Established Credibility: Avience Biomedicals has earned the trust of its customers by consistently delivering reliable healthcare products. Long-standing relationships with healthcare institutions support its position in the market.
- International Presence: Through dedicated export and international marketing efforts, the company has expanded into global markets, diversifying its revenue base and reducing dependence on a single geography.
- Strategic Expansion: The upcoming manufacturing facility in the YEIDA Medical Device Park is expected to provide access to a specialised healthcare ecosystem, supporting future growth, collaboration, and operational scalability.
Risks of Avience Biomedicals
A thorough assessment of the company’s risk factors can help investors make a more informed investment decision.
- Compliance Requirements: The healthcare and diagnostics industry is subject to strict regulatory standards. Changes in rules, approval delays, product recalls, or non-compliance could affect operations, profitability, and market access.
- Import Dependency: The company sources a portion of its raw materials and components from overseas markets, particularly China. Trade restrictions, supply chain disruptions, or higher import duties may increase costs.
- Concentrated Supplier Base: A large share of purchases is sourced from a small group of suppliers. Dependence on limited vendors increases the risk of supply disruptions and procurement challenges.
- High Working Capital Needs: The business requires considerable working capital to maintain inventory and support growth. Inability to secure adequate funding could constrain future expansion plans.
- Trading Revenue Exposure: From the company’s revenue, a significant part is derived from the distribution and resale of third-party medical devices and diagnostic equipment. Any disruption could affect overall business performance.
Avience Biomedicals IPO Review
Avience Biomedicals operates in the growing diagnostics and medical devices segment, a space supported by rising healthcare spending and increasing demand for testing solutions. A board product mix, talented workers, and manufacturing expansion support the company. The healthy GMP also works in its favour. However, investors should note its dependence on trading revenue, working capital requirements, and regulatory risks.
While the opportunity appears promising, the investment decision should be taken by assessing the valuation, financial performance, and business fundamentals.
Other Recent IPO List
Looking for new investment opportunities? Track the upcoming IPOs and the latest market developments.
| Clay Craft India IPO | Diksha Polymers IPO |
| Susan Electricals India IPO | Horizon Reclaim (India) IPO |
| Saffron Speciality Papers IPO | Aastha Spintex IPO |
| GenXAI Analytics IPO | UHM Vacation IPO |
Avience Biomedicals IPO FAQs
Avience Biomedicals IPO is a ₹30 crore NSE SME issue comprising a fresh issue of 14,53,800 shares. The price band has been fixed at ₹196 to ₹208 per share.
Investors can apply through their stockbroker or a supported banking platform using the ASBA facility. UPI-based applications can also be submitted through eligible broker apps.
The company operates in the growing diagnostics and medical devices sector and has shown business growth in recent years. Investors should evaluate the valuation, financials, growth prospects, and risk factors before investing.
Based on the latest GMP of ₹75, the shares are expected to list around ₹283, implying gains of approximately 36%. However, listing gains are not guaranteed.
The Avience Biomedicals IPO will open for subscription on June 18, 2026, and close on June 22, 2026.
The lot size is 600 shares. Retail investors must apply for a minimum of 2 lots, or 1,200 shares, requiring an investment of ₹2,49,600 at the upper price band.
The allotment for Avience Biomedicals IPO is expected to be finalised on June 23, 2026.
The shares are scheduled to be listed on the NSE SME platform on June 25, 2026
